COLUMBUS and CLEVELAND, Ohio – Ohio Governor Mike DeWine, along with Hikma Pharmaceuticals, JobsOhio, the City of Bedford, and other state and local partners, today announced plans for a significant ...
BOSTON (Reuters) -A division of French advertising company Publicis Groupe SA and drug company Hikma Pharmaceuticals have reached separate settlements worth a collective $500 million to resolve claims ...
1mon
Hikma Pharmaceuticals Reiterates 2026 Guidance, Exits 503B Compounding in April Trading Update Call
Hikma Pharmaceuticals (LON:HIK) said it has made an “encouraging start” to 2026 and reiterated its full-year group guidance, ...
On August 22, 2024, Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals, PLC (collectively Hikma), filed a petition for rehearing en banc, asking the US Court of Appeals for the Federal Circuit ...
(RTTNews) - UK-based Hikma Pharmaceuticals PLC announced that its unit Hikma Pharmaceuticals USA, Inc. is extending recall of one lot of Acetaminophen Injection, 1000mg/100mL, (10mg/mL) bags to the ...
A multistate settlement in principle with opioid manufacturer Hikma Pharmaceuticals (Hikma) for its role in fueling the opioid crisis will provide $150 million to resolve claims by states and local ...
Hikma Pharmaceuticals has seen its model fair value edge from £18.84 to £18.74 per share, alongside reduced Street price targets such as 1,800 GBp from 2,300 GBp and 2,000 GBp from 2,400 GBp. Analysts ...
Hikma Pharmaceuticals PLC HIK shares slid 1.20% to £14.77 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 0.75% to 10,425.
Hikma Pharmaceuticals USA will invest $1 billion by 2030 to further expand its U.S. manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines ...
Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries
Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries 02.10.2023 / 06:00 GMT/BST Dublin, Ireland 02 October 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results